Synopsis: Mitchell and colleagues report the induction of a grade 3 immunologic reaction in a patient with glioblastoma receiving autologous RNA-pulsed dendritic-cell vaccines admixed with GM-CSF and coordinated cycles of temozolomide, highlighting the capacity for potent immunologic induction with this regimen.
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PD-L1 Expression Correlates with TumorInfiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly, Jason R. Brown, Kurt Schalper, Herbert Haack, Matthew R. Silver, Christian Nixon, Veerle Bossuyt, Lajos Pusztai, Donald R. Lannin, and David L. Rimm Synopsis: Wimberly and colleagues analyzed pretreatment biopsies and outcomes from 105 breast cancer patients; they report the association of PD-L1 expression with hormone receptor-negative and triple-negative status and pathologic complete responseand suggest that PD-L1 expression is a biomarker in this treatment cohort.
333
Targeting CD20
þ Aggressive B-cell NonHodgkin Lymphoma by Anti-CD20 CAR mRNAModified Expanded Natural Killer Cells In Vitro and in NSG Mice Yaya Chu, Jessica Hochberg, Ashlin Yahr, Janet Ayello, Carmella van de Ven, Matthew Barth, Myron Czuczman, and Mitchell S. Cairo Synopsis: Chu and colleagues show that K562-mbIL15-41BBL-expanded peripheral blood NK cells, modified with mRNA nucleofection of an anti-CD20 CAR, significantly enhanced cytotoxicity against CD20 + B-cell non-Hodgkin lymphoma, extended survival time, and reduced tumor size in xenografted NSG mice.
345
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen Andrew B. Sharabi, Christopher J. Nirschl, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Esteban Velarde, Theodore L. Deweese, and Charles G. Drake Synopsis: Sharabi and colleagues show in two mouse tumor models that radiotherapy combined with PD-1 blockade or Treg depletion improves local tumor control by increasing antigen-experienced and effector-memory T cells, antigen-MHC complexes, and T-cell infiltration into tumors via antigen cross-presentation in the tumor-draining lymph node. 
412
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8 þ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo, Lanqing Huang, Alexandra B. Pucsek, Minwei Cao, Sara Solt, Todd Armstrong, and Elizabeth Jaffee Synopsis: Kouo and colleagues report the development of neutralizing Abs to galectin-3 in PDA patients who showed improved survival in response to a GM-CSF-secreting allogeneic tumor vaccine, and they propose that carbohydrate signaling be considered as "signal 4" of immune-cell programming and differentiation.
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ABOUT THE MASTER
Ellis L. Reinherz, MD, is a professor of medicine at Harvard Medical School (HMS) and chief of the Laboratory of Immunobiology and codirector of the Cancer Vaccine Center at the Dana-Farber Cancer Institute (DFCI). Dr. Reinherz is known for his basic research that has revealed key functional and structural discoveries about TCRs, including their CD3 signaling subunit components, and how the TCRs, along with the CD4 and CD8 coreceptor molecules that he identified, bind to the pMHC. More recently he and his colleagues have defined the TCR as an anisotropic mechanosensor, offering a physical solution to the longstanding question of how T cells can achieve rapid and specific sensing of a single peptide bound to an MHC molecule among a sea of unrelated peptides arrayed on the surface of an antigen-presenting cell with exquisite specificity and dynamic range. His findings on the molecular basis of adaptive immunity have implications for rational vaccine design and human immunotherapy efforts in the clinic. He has authored more than 400 research publications in human and murine immunology, spanning areas in basic and translational research. The development of OKT3, the first FDA-approved monoclonal antibody (mAb) in humans, resulted from his studies demonstrating the ability of the mAb to inhibit antigen-specific T-cell responses.
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ABOUT THE COVER
The surface of an antigen-presenting cell (APC) displays a large array of peptides bound to a major histocompatibility molecule (pMHC). Yet, the specific pMHC against which a T cell is directed is often displayed at a very low (i.e., even single digit) copy number among 50,000 to 100,000 other pMHC molecules. These pMHC complexes comprise the same MHC molecule and similarly sized but distinct peptides. How can a T-cell scan and use its T-cell receptor (TCR) machinery to find a "needle in a haystack"? The solution has been achieved through the evolution of the ab TCR as a mechanosensor. As a result, CD8 cytotoxic T lymphocytes (CTL) and CD4 helper T cells manifest extraordinary ligand sensitivity and specificity. This cover image offers an artist's rendition of MHC molecules projecting from the plasma membrane of an APC. In this case, only one peptide, represented by the small dot in yellow near the periphery of the circle, is the target of that TCR's specificity. Thus, the TCR must mediate T-cell recognition in a chemically complex environment with the ability to finely discriminate among peptides of like size and charge, including tumor antigens for effective elimination of cancers. This figure was rendered by Steve Moskowitz of Advanced Medical Graphics, Boston, MA. For details, see the Masters of Immunology article by Ellis L. Reinherz that begins on page 305 of this issue. 
